

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WALLACH=16A

In re Application of: ) Art Unit: 1642  
)  
David WALLACH et al ) Examiner:  
)  
Appln. No.: Not Received; )  
Continuation of 08/860,082 )  
f. August 19, 1997 ) Washington, D.C.  
)  
Filed: On even date herewith ) April 3, 2001  
)  
For: MODULATORS OF THE )  
FUNCTION OF FAS/APO1 )  
RECEPTORS )

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend as  
follows:

IN THE SPECIFICATION

Please add the following new section to page 1,  
after the Title and before "Field of the Invention":

--Cross-Reference to Related Applications

The present application is a continuation of U.S.  
application no. 08/860,0082, filed August 19, 1997, which is  
the U.S. national stage under 35 U.S.C. §371 of international  
application PCT/US95/16542, filed December 14, 1995,

designating the United States. The international application was published in English. The entire contents of each of said applications are hereby incorporated herein by reference.--

Please replace the paragraph beginning at page 14, line 20, with the following rewritten paragraph:

--Fig. 4 depicts schematically the preliminary nucleotide (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of HF1, as described in Example 1, in which the 'death domain' is underlined as is a possible translation start site, i.e. the underlined methionine residue at position 49 (bold, underlined M). The asterisk indicates the translation stop codon (nucleotides 769-771). At the beginning and in the middle of each line are provided two numerals depicting the relative positions of the nucleotides and amino acids of the sequence with respect to the start of the sequence (5' end), in which the first numeral denotes the nucleotide and the second numeral denoted the amino acid.--

REMARKS


The amendments hereinabove are made to add a "Cross-Reference to Related Applications" section and to insert the same amendment to the specification which was made during prosecution of the parent application.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Roger L. Browdy  
Registration No. 26,618

RLB:rd

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

F:\I\in12\Wallach16A\Pto\AmendA.doc

Version with Markings to Show Changes Made

In the specification:

A new paragraph was added at page 1, after the Title and before "Field of the Invention".

Paragraph beginning at line 20 of page 14 has been amended as follows:

Figs. Fig. 4 depicts schematically the preliminary nucleotide (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of HF1, as described in Example 1, in which the 'death domain' is underlined as is a possible translation start site, i.e. the underlined methionine residue at position 49 (bold, underlined M). The asterisk indicates the translation stop codon (nucleotides 769-771). At the beginning and in the middle of each line are provided two numerals depicting the relative positions of the nucleotides and amino acids of the sequence with respect to the start of the sequence (5' end), in which the first numeral denotes the nucleotide and the second numeral denoted the amino acid.